Decrease (-) Restore Default Increase (+)
CornerStone Vol. 24, No. 2 Fall 2014
vol24_no2_2014.jpg
Front page...

First-Rate Pulmonary Rehab Program Helps 9/11 First Responder Get His Life Back
NYU Winthrop Elects Two New Members to its Board of Directors
NYU Winthrop Opens Urgent Care Center
U.S. News & World Report Names NYU Winthrop Among the Best in the New York Metro Area
At NYU Winthrop, No Man is an Island
Spotlight on Community Gifts Campaign
Hospital Participates in Major International Trial
Generous Grant Supports Alzheimer's Research at NYU Winthrop
NYU Winthrop Opens New Center for Adult Congenital Heart Disease
New Treatment Improves the Lives of Patients With MR
Swimming with Purpose: Annual Event Raises Pivotal Support for Child Life Program
A Cause to Celebrate Raises More Than $147,000 for Child Life Program
A Celebration of Life: NYU Winthrop's 16th Annual Cancer Survivor's Day
Unique Partnership Supports Families Facing Perinatal Mood & Anxiety Disorders
29th Annual Golf Tournament Raises $649,000+ for NYU Winthrop Research and Academic Center
Eighth Annual Black & White Ball Raises Nearly $270,000 for NYU Winthrop's CCFK
Eight and Forty Makes Donation to Department of Pediatrics
Richard A. Newhouse, Jr., Receives Lifetime Achievement Award
Long Island Foundation's Generosity Changes Lives at NYU Winthrop's Hempstead Pediatric Clinic
Running for a Reason
National Awards Recognize Quality Breast Health Care
Once Again, NYU Winthrop Earns Designation as a NAEC Level 4 Epilepsy Center
New Patient Family Advisory Council
The STAR Program: Enhancing the Hospital Experience for Children With Special Needs
NYU Winthrop: A Pioneer in the Use of Technology to Enhance Patient Care and Safety
NYU Winthrop Debuts New Ambulances
Nurse Goes Above and Beyond the Call of Duty
NYU Winthrop Receives "Found Money"
Garden City Foundation Continues the Tradition of Making 'Miracles' for NYU Winthrop's CCFK
Twinkle Town Makes Colorful Donation to NYU Winthrop Kids
Milestone Golf Outing to Benefit the CCFK is a Record-Breaking Success
WiSH Clinic Opens
Surviving the Holidays
Hospital Celebrates Expansion With Dedication of New Specialty Center East
NYU Winthrop Unveils New "Welcome" Sign
NYU Winthrop Opens Manhattan's First and Only CyberKnife® Center
 

Generous Grant Supports Alzheimer's Research at NYU Winthrop

executive director and ceo of alzheimers disease resources center Pictured (l.-r.) are Mary Ann Malack-Ragona, Executive Director and CEO of Alzheimer's Disease Resource Center, Inc.; Irving H. Gomolin, MD, Chief, Division of Geriatric Medicine at NYU Winthrop; and Linda Martinez, LCSW, Department of Geriatrics at NYU Winthrop.

Representatives from the Alzheimer's Disease Resource Center (ADRC) recently visited NYU Winthrop to present a $3,000 check to Irving H. Gomolin, MD, Chief of the Division of Geriatric Medicine at NYU Winthrop. The grant will assist Dr. Gomolin's research on how the removal of Namenda from the marketplace and substitution with an extended release formulation will impact the blood levels of patients with Alzheimer's Disease or dementia.

Namenda (also known as memantine) is an oral medication used to treat moderate to severe dementia related to Alzheimer's Disease. While it does not cure the disease, it may improve memory, awareness and the ability to perform daily functions. The standard tablet formulation of the drug was removed from the marketplace in August 2014 without any available generic versions in the United States because patent rights to the drug do not expire until 2015. Instead, Alzheimer's patients can be switched to an extended release formulation of memantine.

In this study, Dr. Gomolin, in collaboration with his research colleagues, Allison Reiss, MD, Head, Inflammation Section, NYU Winthrop Research Institute, and Morgan Peltier, PhD, Lead Scientist, Women's and Children's Health Section, will measure whether the switch from the standard tablets to the extended release formulation will result in important changes in blood concentrations of this medication among patients with Alzheimer's Disease or dementia.

"The research funds offer support to show how the pharmacologic change will affect patients following the drug manufacturer's decision to limit the various memantine formulations currently available," said Dr. Gomolin. "It also helps provide the opportunity to partner with local nursing homes who care for patients with Alzheimer's Disease."

The grant came from part of an anonymous donation that ADRC recently received. This was the first research study the organization has funded.